Toggle Nav

Pioglitazone

In stock
Catalog No.
B2117
PPAR agonist
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$80.00
In stock
10mg
$60.00
In stock
50mg
$100.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Pioglitazone (U 72107) is a selective peroxisome proliferator-activated receptor gamma(PPARγ) stimulator.

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt356.44
Cas No.111025-46-8
FormulaC19H20N2O3S
Solubility≥14.3mg/mL in DMSO
Chemical Name5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
SDFDownload SDF
Canonical SMILESCCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
Shipping ConditionEvaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Protocol

Cell experiment [1]:

Cell lines

HIT-T15(a pancreatic beta cell line)

Preparation method

The solubility of this compound in DMSO is >14.3mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

0.5 or 1 μmol/l for 5 days

Applications

AGEs (Advanced Glycation End-Products)-induced beta cell necrosis was completely abrogated by adding Pioglitazone to the AGEs culture medium. Pioglitazone was able to counteract AGE-induced pancreatic beta cell death and dysfunction (Adding 1 μmol/l, but not 0.5 of Pioglitazone). Taken together, pioglitazone improved insulin secretory capacity, preserving beta cell mass and islet structure and protecting beta cells from oxidative stress, as well as, improving beta cell function.

Animal experiment [2]:

Animal models

Eight-week-old male C57/Bl6 mice

Dosage form

20 mg/kg per day

Application

Mice treated with pioglitazone were partially protected from MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine )-induced decrease of striatal dopamine concentrations at 7 days and a lower activation of microglia and less GFAP(glial fibrillary acidic protein )-positive cells in both striatum and SNpc after two and five injections of MPTP. Thus, treatment with pioglitazone completely protected TH-positive cells from MPTP toxicity in this chronic model of PD (Parkinson’s disease). In mice treated with pioglitazone, there were a reduced activation of microglia, reduced induction of NOS (NO synthase)-positive cells and less glial fibrillary acidic protein positive cells in both striatum and substantia nigra pars compacta. In addition, treatment with pioglitazone almost completely blocked staining of TH-positive neurons for nitrotyrosine, a marker of NO (nitric oxide)-mediated cell damage.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Puddu A, et al. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Regul Pept. 2012 Aug 20;177(1-3):79-84.

[2]. Dehmer T1, Heneka MT, et al. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem. 2004 Jan;88(2):494-501.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

Pioglitazone